Advarra purchases IRBco

By Jenni Spinner contact

- Last updated on GMT

(Image: Getty/metamorworks)
(Image: Getty/metamorworks)

Related tags: acquisition, advarra, Irb

The institutional review board and research technology solutions provider has acquired IRBco to expand its reach and presence in North America.

Advarra—which provides institutional review board (IRB), institutional biosafety committee, research technology solutions, and quality/compliance consulting services—has purchased IRB Company (IRBco). IRBco is an AAHRPP-accredited central IRB in operation since 1981.

According to Gadi Saarony, Advarra CEO, the acquisition will enable his company to further its mission to empower clinical trials to do their work, and to advance human health.

IRBco studies will be fully integrated with Advarra in a matter of weeks, and we look forward to the additional talent and board expertise this will bring to our organization​,” he said. “We will maintain our focus on developing altogether better capabilities that serve clients and protect research participants​.”

Advarra offers a range of products and services designed to streamline processes, create efficiencies, and support research compliance. These capabilities are intended to provide the research and biopharmaceutical industries with integrated solutions.

According to Advarra, the acquisition will increase its reach to more than 3,200 research institutions, hospital systems, and academic medical centers.

Anil Sharma, CEO of IRBco, said joining forces makes sense for both companies, and their clients.

Joining the Advarra family is an ideal fit​,” he said. “We are pleased to offer our mutual customers expanded resources—innovations, efficiencies, and all the characteristics to collaboratively complement moving research forward​.”

Overall, Advarra offers technology products and consulting services that are geared toward accelerating research through technologies, strategic partnerships, and customer-centric service. According to the company, the approach reduces operational costs, streamlines study startup activities, prevents errors and administrative burdens, and saves time for clinical research sponsors, CROs, investigators, and institutions.

Related news

Show more

Related products

show more

What should a clinical metadata repository do?

What should a clinical metadata repository do?

Formedix | 26-Jul-2021 | Technical / White Paper

Choosing a clinical metadata repository (MDR) software can be a tough task as the capabilities and features of your chosen MDR could make or break your...

Adapting supply chains to new ways of working

Adapting supply chains to new ways of working

World Courier | 15-Jul-2021 | Technical / White Paper

COVID-19 has changed the way we operate. We have adapted our supply chain solutions to meet our clients’ requirements while following World Courier standard...

Empowering Clinical Trial Sponsors with Analytics

Empowering Clinical Trial Sponsors with Analytics

PerkinElmer | 14-Jul-2021 | Technical / White Paper

Is your Clinical Data Review creating problems or solving them? Take Control of Your Data. PerkinElmer Informatics Clinical Solutions, powered by Tibco...

What are the building blocks of DCTs?

What are the building blocks of DCTs?

Medable | 26-Apr-2021 | Technical / White Paper

How to create a seamless experience across eConsent, eCOA and more.

Over the past year, tremendous progress was made toward digitizing and...

Related suppliers

Follow us

Products

View more

Webinars